Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking and Finance Review

Company

    GBAF Logo
    • About Us
    • Profile
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release
    • Awards▾
      • About the Awards
      • Awards TimeTable
      • Submit Nominations
      • Testimonials
      • Media Room
      • Award Winners
      • FAQ
    • Magazines▾
      • Global Banking & Finance Review Magazine Issue 79
      • Global Banking & Finance Review Magazine Issue 78
      • Global Banking & Finance Review Magazine Issue 77
      • Global Banking & Finance Review Magazine Issue 76
      • Global Banking & Finance Review Magazine Issue 75
      • Global Banking & Finance Review Magazine Issue 73
      • Global Banking & Finance Review Magazine Issue 71
      • Global Banking & Finance Review Magazine Issue 70
      • Global Banking & Finance Review Magazine Issue 69
      • Global Banking & Finance Review Magazine Issue 66
    Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2026 GBAF Publications Ltd - All Rights Reserved. | Sitemap | Tags

    Editorial & Advertiser disclosure

    Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Home > Finance > Obesity stocks slump on Novo's underwhelming 2026 sales forecast
    Finance
    Obesity stocks slump on Novo's underwhelming 2026 sales forecast

    Published by Global Banking and Finance Review

    Posted on February 3, 2026

    2 min read

    Last updated: February 3, 2026

    Obesity stocks slump on Novo's underwhelming 2026 sales forecast - Finance news and analysis from Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Tags:market capitalisationFinancial performanceinvestment portfolioscorporate governancehealthcare expenditure

    Quick Summary

    Novo Nordisk's 2026 sales forecast causes obesity stocks to slump, with shares of major drugmakers like Eli Lilly and Structure Therapeutics falling significantly.

    Table of Contents

    • Impact of Novo Nordisk's Sales Forecast on Obesity Stocks
    • Market Reactions and Stock Performance
    • Analysts' Revised Market Expectations
    • Novo Nordisk's Financial Performance

    Novo Nordisk's 2026 Sales Forecast Triggers Obesity Stocks Decline

    Impact of Novo Nordisk's Sales Forecast on Obesity Stocks

    Feb 3 (Reuters) - Shares of obesity drugmakers and developers slid on Tuesday after Novo Nordisk forecast a sharper-than-expected sales decline for 2026, underscoring intensifying competition in the blockbuster weight-loss market.

    Market Reactions and Stock Performance

    Eli Lilly was down about 4%, Structure Therapeutics fell 6.2%, while Altimmune dropped 4.2%. Viking Therapeutics declined more than 3% and Amgen slipped nearly 1% in afternoon trading.

    Analysts' Revised Market Expectations

    The Danish drugmaker said it expects sales to drop between 5% and 13% this year, compared with analysts' average expectation of a 2% decline. Its U.S.-listed shares fell 13.8% to $50.83.

    Novo Nordisk's Financial Performance

    Wegovy-maker Novo also reported a 14% fall in fourth-quarter operating profit to 31.7 billion Danish crowns, slightly above the estimate of 31.2 billion crowns.

    The selloff comes as Wall Street is reassessing long-held expectations that the obesity drug market could hit $150 billion early next decade, as U.S. prices for GLP-1 treatments from Novo and Lilly fall sharply and competition intensifies in the cash-pay consumer market.

    Analysts have pushed out peak sales timelines and trimmed forecasts, with some now seeing the market closer to $80 billion to $105 billion by 2030.

    ($1 = 6.3201 Danish crowns)

    (Reporting by Mrinalika Roy in Bengaluru; Editing by Shilpi Majumdar)

    Key Takeaways

    • •Novo Nordisk forecasts significant sales decline for 2026.
    • •Obesity drugmakers' shares fall sharply in response.
    • •Eli Lilly, Structure Therapeutics, and others see stock drops.
    • •Analysts revise obesity drug market expectations downward.
    • •Intense competition impacts GLP-1 treatment prices.

    Frequently Asked Questions about Obesity stocks slump on Novo's underwhelming 2026 sales forecast

    1What is market capitalisation?

    Market capitalisation is the total market value of a company's outstanding shares of stock, calculated by multiplying the share price by the total number of shares.

    2What is an obesity drug?

    An obesity drug is a medication designed to assist in weight loss by suppressing appetite, increasing feelings of fullness, or reducing fat absorption.

    3What is stock performance?

    Stock performance refers to the change in the value of a company's stock over time, which can be influenced by various factors including market conditions and company performance.

    More from Finance

    Explore more articles in the Finance category

    Renault to use Chinese parts for EV engine to be assembled in France 
    Santander to buy Webster Financial in $12.2 billion to create top-10 retail bank in U.S
    Knight Vinke founder says his fund can't invest in uncertain US under Trump
    Wegovy maker Novo Nordisk appoints Jamey Millar head of its US business
    Lithuania launches human trafficking probe related to Epstein files
    Novo Nordisk warns on profits and sales amid Trump drug price crackdown
    Chocolate maker Tony's Chocolonely says lower cocoa price offers chance to bolster supply chain 
    Slovenian lawmakers make acting central bank head Dolenc's role permanent
    Europe must keep control of key technologies, says EU commissioner
    Russia's Putin and Saudi crown prince discuss work of OPEC+, Kremlin says
    UK's power firm Drax Group says it could cut over 10% jobs
    German voice actors boycott Netflix over AI training concerns
    View All Finance Posts
    Previous Finance PostSantander to buy Webster Financial in $12.2 billion to create top-10 retail bank in U.S
    Next Finance PostKnight Vinke founder says his fund can't invest in uncertain US under Trump